Therapeutic Area | MeSH |
---|---|
infections | D007239 |
neoplasms | D009369 |
digestive system diseases | D004066 |
Brand Name | Status | Last Update |
---|---|---|
equaline lansoprazole | ANDA | 2023-08-02 |
equate lansoprazole delayed release | ANDA | 2019-11-21 |
kirkland signature lansoprazole delayed release | ANDA | 2020-03-23 |
lansoprazole | ANDA | 2018-09-24 |
lansoprazole, amoxicillin, clarithromycin | ANDA | 2023-09-18 |
prevpac | New Drug Application | 2010-03-15 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Lansoprazole, Lansoprazole, Dexcel | |||
11077055 | 2036-04-21 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | 11 | 9 | 12 | 17 | 14 | 59 |
Healthy volunteers/patients | — | — | — | 26 | — | 1 | 4 | — | 31 |
Infections | D007239 | EFO_0000544 | — | 1 | — | 8 | 14 | 5 | 28 |
Esophagitis | D004941 | HP_0100633 | K20 | 2 | 5 | 9 | 3 | — | 19 |
Stomach ulcer | D013276 | — | K25 | — | — | 11 | 1 | 1 | 13 |
Heartburn | D006356 | — | R12 | 3 | 2 | 4 | 2 | — | 10 |
Peptic ulcer | D010437 | HP_0004398 | K27 | — | — | 3 | 4 | 1 | 8 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | 4 | 1 | 2 | 7 |
Laryngopharyngeal reflux | D057045 | EFO_1001355 | — | 1 | — | — | 3 | 3 | 7 |
Peptic esophagitis | D004942 | EFO_1001095 | — | — | 1 | 5 | 1 | — | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Duodenal ulcer | D004381 | EFO_0004607 | K26 | — | — | 10 | — | 2 | 12 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | 1 | — | — | 3 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 2 | 1 | — | — | 3 |
Gout | D006073 | EFO_0004274 | M10 | — | 1 | 1 | — | — | 2 |
Lymphoma | D008223 | — | C85.9 | — | — | 1 | — | 1 | 2 |
Covid-19 | D000086382 | — | U07.1 | — | — | 1 | — | 1 | 2 |
Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | 1 | — | — | 1 |
Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | — | 1 |
Communicable diseases | D003141 | — | — | — | — | 1 | — | — | 1 |
Human experimentation | D006805 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 1 | — | — | — | 1 |
Uterine neoplasms | D014594 | EFO_0003859 | C55 | — | 1 | — | — | — | 1 |
Uterine cervical neoplasms | D002583 | HP_0030159 | — | — | 1 | — | — | — | 1 |
Heart valve diseases | D006349 | EFO_0009551 | I08 | — | 1 | — | — | — | 1 |
Rectal neoplasms | D012004 | — | — | — | 1 | — | — | — | 1 |
Avulsion fractures | D000071562 | — | — | 1 | 1 | — | — | — | 1 |
Appendiceal neoplasms | D001063 | EFO_0003880 | C18.1 | — | 1 | — | — | — | 1 |
Pseudomyxoma peritonei | D011553 | EFO_0007456 | — | — | 1 | — | — | — | 1 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | 1 | — | — | — | 1 |
Deglutition disorders | D003680 | HP_0002015 | R13.1 | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Homeostasis | D006706 | — | — | 1 | — | — | — | — | 1 |
Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
Mouth neoplasms | D009062 | EFO_0003868 | C06.9 | 1 | — | — | — | — | 1 |
Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | — | — | — | — | 1 |
Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Calcium metabolism disorders | D002128 | EFO_0005769 | E83.5 | — | — | — | — | 2 | 2 |
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
Aortic valve disease | D000082862 | — | — | — | — | — | — | 1 | 1 |
Non-erosive reflux disease | D000096663 | — | — | — | — | — | — | 1 | 1 |
Sudden death cardiac | D016757 | EFO_0004278 | — | — | — | — | — | 1 | 1 |
Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | — | 1 | 1 |
Glomerulonephritis | D005921 | HP_0000099 | N05 | — | — | — | — | 1 | 1 |
Membranous glomerulonephritis | D015433 | EFO_0004254 | N03.2 | — | — | — | — | 1 | 1 |
Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | — | — | — | 1 | 1 |
Chronic periodontitis | D055113 | EFO_0006343 | K05.3 | — | — | — | — | 1 | 1 |
Drug common name | Lansoprazole |
INN | lansoprazole |
Description | Lansoprazole is a member of benzimidazoles, a member of pyridines and a sulfoxide. It has a role as an EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor and an anti-ulcer drug. |
Classification | Small molecule |
Drug class | antiulcer agents (benzimidazole derivatives) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1 |
PDB | — |
CAS-ID | 103577-45-3 |
RxCUI | — |
ChEMBL ID | CHEMBL480 |
ChEBI ID | 6375 |
PubChem CID | 3883 |
DrugBank | DB00448 |
UNII ID | 0K5C5T2QPG (ChemIDplus, GSRS) |